Trial Profile
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Aug 2015 New trial record